



US 20210253679A1

(19) **United States**(12) **Patent Application Publication**
HUSSACK et al.(10) **Pub. No.: US 2021/0253679 A1**(43) **Pub. Date: Aug. 19, 2021**(54) **SERUM ALBUMIN BINDING ANTIBODIES
FOR TUNEABLE HALF-LIFE EXTENSION
OF BIOLOGICS****Publication Classification**(51) **Int. Cl.**
C07K 16/18 (2006.01)(52) **U.S. Cl.**
CPC **C07K 16/18** (2013.01); **C07K 2317/24**
(2013.01); **C07K 2317/565** (2013.01); **C07K**
2317/569 (2013.01)(71) Applicant: **National Research Council of
Canada, Ottawa (CA)**(72) Inventors: **Gregory HUSSACK, Ottawa (CA);
Jamshid TANHA, Orleans (CA);
Kevin HENRY, Ottawa (CA); Traian
SULEA, Kirkland (CA)**(21) Appl. No.: **17/050,072**(22) PCT Filed: **Apr. 24, 2019**(86) PCT No.: **PCT/CA2019/050514**

§ 371 (c)(1),

(2) Date: **Oct. 23, 2020****Related U.S. Application Data**(60) Provisional application No. 62/661,871, filed on Apr.
24, 2018.(57) **ABSTRACT**

The present document describes an antibody or an antigen-binding fragment that bind to serum albumin comprising three complementarity determining regions (CDR1, CDR2 and CDR3), for half-life extension of biologics. The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of removing molecules from serum.

Specification includes a Sequence Listing.